Q-linea signs distribution agreement for Norway
Q-linea signs distribution agreement for Norway
Q-linea AB (publ) (OMX: QLINEA) today announces that the company has signed an exclusive distribution agreement for Norway with Montebello Diagnostics AS.
In line with Q-linea’s strategy to achieve a wider reach for ASTar, Q-linea has signed a distribution agreement with Montebello Diagnostics AS, which gives the exclusive right to sell ASTar Instrument and associated consumables in Norway. Due to long sales cycles, the agreement will primarily affect 2024 sales.
“Montebello Diagnostics is well known for its competence in bacteriology and for its product range aimed at microbiological hospital laboratories. That makes them a perfect partner for us, and I look forward to a fruitful collaboration. The partnership is proof that we are following our commercialization strategy and that there is high interest in distributing ASTar,” said Jonas Jarvius, CEO of Q-linea.
About ASTar Instruments and ASTar BC G-Kit
ASTar Instrument and ASTar BC G-Kit already deliver the broadest answer regarding the combination of the number of antibiotics and the number of double dilution steps of each antibiotic, in a single analysis for gram-negative bacteria. The test enables the analysis of gram-negative bacteria, including difficult-to-grow so-called fastidious bacteria, which satisfies the need for rapid and comprehensive results to support optimal treatment decisions.
ASTar Instrument and ASTar BC G- Kit are CE-marked but not FDA 510(k)-cleared and not available for sale in the United States.